Athena Philis-Tsimikas1, Irene Stratton2, Lone Nørgård Troelsen3, Britta Anker Bak3, Lawrence A Leiter4. 1. 1 Scripps Whittier Diabetes Institute, La Jolla, CA, USA. 2. 2 Gloucestershire Retinal Research Group, Cheltenham General Hospital, Gloucestershire, UK. 3. 3 Novo Nordisk A/S, Søborg, Denmark. 4. 4 Li Ka Shing Knowledge Institute, Division of Endocrinology and Metabolism, St Michael's Hospital, University of Toronto, Toronto, Canada.
Abstract
BACKGROUND: A head-to-head trial (NCT03078478) between insulin degludec and insulin glargine U300 with the primary objective of comparing the risk of hypoglycemia is being conducted. During trial conduct, safety concerns related to the glycemic data collection system led to a postinitiation protocol amendment, described here. METHODS: This randomized (1:1), open-label, treat-to-target, multinational trial was initiated in March 2017 with a planned treatment period of 52 weeks (16 weeks titration + 36 weeks maintenance). Overall, ~1600 insulin-experienced patients at risk of developing hypoglycemia based on predefined risk factors were included. The protocol amendment implemented in February 2018 resulted in assuring patient safety and an extension of the total treatment period up to 88 weeks (16 weeks titration + variable maintenance 1 + 36 weeks maintenance 2). The original glycemic data collection system (MyGlucoHealth blood glucose meter + electronic diary) was discontinued because of safety concerns and replaced with an Abbott blood glucose meter and paper diary to collect self-measured blood glucose and hypoglycemic episodes. The primary endpoint of number of severe or blood-glucose confirmed symptomatic hypoglycemic episodes will be evaluated with the same analysis duration and statistical methods as the original protocol. Only relevant changes were implemented to maintain patient safety while permitting evaluation of the scientific objectives of the trial. CONCLUSIONS: These observations highlight the importance of safety surveillance during trial conduct despite the use of currently marketed glucose monitoring devices. The prompt protocol amendment and ensuing actions ensured that the scientific integrity of the trial was not compromised.
RCT Entities:
BACKGROUND: A head-to-head trial (NCT03078478) between insulin degludec and insulinglargine U300 with the primary objective of comparing the risk of hypoglycemia is being conducted. During trial conduct, safety concerns related to the glycemic data collection system led to a postinitiation protocol amendment, described here. METHODS: This randomized (1:1), open-label, treat-to-target, multinational trial was initiated in March 2017 with a planned treatment period of 52 weeks (16 weeks titration + 36 weeks maintenance). Overall, ~1600 insulin-experienced patients at risk of developing hypoglycemia based on predefined risk factors were included. The protocol amendment implemented in February 2018 resulted in assuring patient safety and an extension of the total treatment period up to 88 weeks (16 weeks titration + variable maintenance 1 + 36 weeks maintenance 2). The original glycemic data collection system (MyGlucoHealth blood glucose meter + electronic diary) was discontinued because of safety concerns and replaced with an Abbott blood glucose meter and paper diary to collect self-measured blood glucose and hypoglycemic episodes. The primary endpoint of number of severe or blood-glucose confirmed symptomatic hypoglycemic episodes will be evaluated with the same analysis duration and statistical methods as the original protocol. Only relevant changes were implemented to maintain patient safety while permitting evaluation of the scientific objectives of the trial. CONCLUSIONS: These observations highlight the importance of safety surveillance during trial conduct despite the use of currently marketed glucose monitoring devices. The prompt protocol amendment and ensuing actions ensured that the scientific integrity of the trial was not compromised.
Authors: Andreas Pfützner; Filiz Demircik; Valeria Kirsch; Johannes Pfützner; Stephanie Strobl; Mina Hanna; Jan Spatz; Anke H Pfützner Journal: J Diabetes Sci Technol Date: 2019-04-11
Authors: Yoichiro Hirakawa; Hisatomi Arima; Sophia Zoungas; Toshiharu Ninomiya; Mark Cooper; Pavel Hamet; Giuseppe Mancia; Neil Poulter; Stephen Harrap; Mark Woodward; John Chalmers Journal: Diabetes Care Date: 2014-05-08 Impact factor: 19.112
Authors: Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin Journal: J Am Coll Cardiol Date: 2009-01-20 Impact factor: 24.094
Authors: Simon R Heller; Richard M Bergenstal; William B White; Stuart Kupfer; George L Bakris; William C Cushman; Cyrus R Mehta; Steven E Nissen; Craig A Wilson; Faiez Zannad; Yuyin Liu; Noah M Gourlie; Christopher P Cannon Journal: Diabetes Obes Metab Date: 2017-02-27 Impact factor: 6.577
Authors: Carol Wysham; Anuj Bhargava; Louis Chaykin; Raymond de la Rosa; Yehuda Handelsman; Lone N Troelsen; Kajsa Kvist; Paul Norwood Journal: JAMA Date: 2017-07-04 Impact factor: 56.272
Authors: Andreas Pfützner; Filiz Demircik; Valeria Kirsch; Johannes Pfützner; Stephanie Strobl; Mina Hanna; Jan Spatz; Anke H Pfützner Journal: J Diabetes Sci Technol Date: 2019-04-11
Authors: Athena Philis-Tsimikas; David C Klonoff; Kamlesh Khunti; Harpreet S Bajaj; Lawrence A Leiter; Melissa V Hansen; Lone N Troelsen; Steen Ladelund; Simon Heller; Thomas R Pieber Journal: Diabetologia Date: 2020-01-27 Impact factor: 10.122
Authors: Thomas R Pieber; Harpreet S Bajaj; Simon R Heller; Ting Jia; Kamlesh Khunti; David C Klonoff; Steen Ladelund; Lawrence A Leiter; Lily Wagner; Athena Philis-Tsimikas Journal: Diabetes Obes Metab Date: 2021-10-17 Impact factor: 6.408